Greg Mullen
Chief Executive Officer
Healthcare Experts
Theragnostics
Spain
Biography
Greg has a career spanning 20-years in radiopharmaceutical research and development. He has gained extensive regulatory, product and clinical development experience doing research and development of vaccines at the U.S. National Institutes of Health. Greg returned to the UK to King’s College London (KCL), where his group developed imaging biomarkers for autoimmunity, heart disease and oncology. While at KCL he co-invented the Galli® technology at the centre of Theragnostics’ proprietary platform. He later became Director of R&D for Oxford Immunotec with responsibility for translating in vitro diagnostic products from bench to bedside.
Research Interest
biomarkers
